News
ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...
Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...
Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...
UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...
Among the guideline’s recommendations is the use of local low-dose vaginal estrogen as first-line therapy for GSM. The recent release of the “Genitourinary Syndrome of Menopause: AUA/SUFU [Society of ...
The relationship between clinical trial results and real-world experience with enzalutamide and darolutamide shows important patterns: The alignment between trial data and clinical experience supports ...
John Michael DiBianco, MD, discusses findings from the BLUES trial. A recent study evaluated silicone vs polyurethane stents found that the primary outcome of pain intensity and interference at 7 to ...
Investigators found that benefits of treatments that are observed in trials also appear in the real world. A recent study examined the relationship between randomized controlled trials and real-world ...
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation. Welcome back to Pearls & Perspectives! In this episode of Pearls & ...
Merrill discusses the evolving non–muscle invasive bladder cancer treatment space. Expanded access programs (EAPs), such as a recently FDA-authorized EAP in which ImmunityBio is partnering with the ...
Please share your concluding thoughts about the recent progress and future outlook of NMIBC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results